U.S. Markets closed

Alzamend Neuro, Inc. (ALZN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0300+0.0200 (+1.98%)
At close: 04:00PM EDT
1.0201 -0.01 (-0.96%)
After hours: 07:35PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0100
Bid1.0100 x 800
Ask1.0500 x 40000
Day's Range0.9800 - 1.0600
52 Week Range0.8010 - 3.6100
Avg. Volume320,367
Market Cap91.516M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1030
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.25
  • InvestorPlace

    6 Penny Stocks With 1,000% Upside Potential

    Investors in penny stocks know that they are an inherently risky proposition. That goes double for any investor just getting into this market. But with great risk comes great reward. In this case, I think these are penny stocks with 1,000% upside potential. That would be a return any investor would love. First, the methodology for assessing upside potential: This is simply a measure of the current price against the target price. So, all of these stocks above could turn $1,000 into $11,000 is ana

  • Benzinga

    Alzamend Neuro Receives Positive FDA Response For Its Depression Candidate

    Alzamend Neuro Inc (NASDAQ: ALZN) has received a written response to its meeting request relating to its Type B Pre-Investigational New Drug (IND) application from the FDA. The FDA’s response provides a path for Alzamend’s planned clinical development of AL001 for bipolar disorder, major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). In Phase 1, a relative bioavailability comparison of AL001 to lithium carbonate completed in March, AL001 was shown to provide dose-normalize

  • Business Wire

    Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

    ATLANTA, July 18, 2022--Alzamend Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depression, and Post-Traumatic Stress Disorder